119 related articles for article (PubMed ID: 2437641)
1. Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125.
Szymendera JJ
Tumour Biol; 1986; 7(5-6):333-42. PubMed ID: 2437641
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
3. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
Wu JT
Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
[TBL] [Abstract][Full Text] [Related]
4. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
Wu JT; Miya T; Knight JA; Knight DP
Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
[TBL] [Abstract][Full Text] [Related]
5. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies.
Staab HJ; Brümmendorf T; Hornung A; Anderer FA; Kieninger G
Klin Wochenschr; 1985 Feb; 63(3):106-15. PubMed ID: 3856076
[TBL] [Abstract][Full Text] [Related]
6. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies.
Charpin C; Bhan AK; Zurawski VR; Scully RE
Int J Gynecol Pathol; 1982; 1(3):231-45. PubMed ID: 6193072
[TBL] [Abstract][Full Text] [Related]
7. [Comparison between the gastrointestinal tumor antigen and the carcinoembryonic antigen in diseases of the digestive tract].
Tappero G; Piantino P; Cerchier A; Pecchio F
Minerva Med; 1985 Apr; 76(16):765-70. PubMed ID: 2582313
[TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of CA 19-9 for the detection of malignant tumors--a comparison with CEA and IAP].
Furukawa M; Kazaka S; Kushibiki K; Ashida Y; Saito H; Yamamoto H; Furukawa T
Gan No Rinsho; 1984 Apr; 30(4):357-62. PubMed ID: 6587133
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
[TBL] [Abstract][Full Text] [Related]
10. Detection of a circulating gastrointestinal cancer antigen in sera of patients with gastrointestinal malignancies by a double determinant immunoassay with monoclonal antibodies against human blood group determinants.
Herlyn M; Shen JW; Sears HF; Civin CI; Verrill HL; Goldberg EM; Koprowski H
Clin Exp Immunol; 1984 Jan; 55(1):23-35. PubMed ID: 6198117
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
[TBL] [Abstract][Full Text] [Related]
12. Human alveolar macrophage-56 and carcinoembryonic antigen monoclonal antibodies in the differential diagnosis between primary ovarian and metastatic gastrointestinal carcinomas.
Fowler LJ; Maygarden SJ; Novotny DB
Hum Pathol; 1994 Jul; 25(7):666-70. PubMed ID: 8026826
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of the circulating tumor-associated antigen CA 19-9 in cancers of the digestive tract].
Staab HJ; Hornung A; Anderer FA; Kieninger G
Dtsch Med Wochenschr; 1984 Jul; 109(30):1141-7. PubMed ID: 6204834
[TBL] [Abstract][Full Text] [Related]
14. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
15. Comparative measurement of ovarian carcinoma antigen and carcinoembryonic antigen in the serum of ovarian cancer.
Yuan CC; Ng HT; Tsai LC; Jeng FS; Yeh SH; Tsai YC
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Aug; 20(3):190-7. PubMed ID: 3480793
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
Ricolleau G; Chatal JF; Fumoleau P; Kremer M; Douillard JY; Curtet C
Tumour Biol; 1984; 5(3-4):151-9. PubMed ID: 6594738
[TBL] [Abstract][Full Text] [Related]
17. Use of four monoclonal antibodies to detect tumor markers.
Kawahara M; Terasaki PI; Chia D; Johnson C; Hermes M; Tokita K
Cancer; 1986 Nov; 58(9):2008-12. PubMed ID: 2428463
[TBL] [Abstract][Full Text] [Related]
18. Value of serum levels of carcinoembryonic antigen, CEA, and gastrointestinal cancer antigen, GICA or CA 19-9, for preoperative staging and postoperative monitoring of patients with colorectal carcinoma.
Szymendera JJ; Nowacki MP; Kozłowicz-Gudzińska I; Kowalska M
Dis Colon Rectum; 1985 Dec; 28(12):895-9. PubMed ID: 3864628
[TBL] [Abstract][Full Text] [Related]
19. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.
Bast RC; Klug TL; Schaetzl E; Lavin P; Niloff JM; Greber TF; Zurawski VR; Knapp RC
Am J Obstet Gynecol; 1984 Jul; 149(5):553-9. PubMed ID: 6204531
[TBL] [Abstract][Full Text] [Related]
20. Immunoradiometric assay of CA 125 in effusions. Comparison with carcinoembryonic antigen.
Pinto MM; Bernstein LH; Brogan DA; Criscuolo E
Cancer; 1987 Jan; 59(2):218-22. PubMed ID: 3467816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
